Clinical trial
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile…
NCT00003557 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00003557 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer |
| Official title | A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer |
| Intervention type | Drug |
| Interventions | dolastatin 10 |
| Enrollment | 16 |
| Start date | Jan 1, 1999 |
| Primary completion | Jun 1, 2000 |
| Completion | Aug 1, 2003 |
| First posted | Jul 22, 2004 |
| Last update posted | Mar 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: